Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Merck Loses Nasonex Patent Ruling Against Apotex in N.J.

June 15 (Bloomberg) -- Merck & Co.’s patent for the allergy drug Nasonex isn’t infringed by Apotex Inc., a federal judge ruled.

U.S. District Judge Peter Sheridan said today that Merck’s Schering unit had “failed to present credible evidence” of infringement, according to a court filing in Trenton, New Jersey. Sheridan also denied Apotex’s claim that Schering’s patent was invalid.

Schering sued Apotex in 2009, claiming that it had filed a new-drug application with the U.S. Food and Drug Administration for a generic nasal spray that would infringe Schering’s patents. The patent at issue in this ruling expires in 2018, Merck said in a statement today.

“We’ll very likely appeal and seek an injunction,” Ron Rogers, a spokesman for Whitehouse Station, New Jersey-based Merck, said in a telephone interview. “As far as we know, the FDA has not approved Apotex’s application. We do not expect generic competition near-term.”

Elie Betito, a spokesman for Toronto-based Apotex, didn’t immediately return messages seeking comment on the ruling.

Apotex claimed that its proposed product -- a nasal spray to reduce symptoms of rhinitis -- has an active ingredient that’s different from Schering’s, according to court papers.

The case is Schering Corp. v. Apotex, 09-06373, U.S. District Court, District of New Jersey (Trenton).

To contact the reporter on this story: Don Jeffrey in New York at djeffrey1@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.